Investigator-Initiated Ph 1 Trial for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma planned
Chief Medical Officer of Elicio Therapeutics, Christopher Haqq, M.D., Ph.D., added, “We believe this study represents a critical step forward in KRAS-targeted immunotherapy. By evaluating ELI-002 in combination with mFOLFIRINOX and exploring the additional role of anti-PD-1 blockade, we aim to establish a treatment paradigm that maximizes immune activation while maintaining safety. Our hope is that this approach will deliver meaningful improvements in relapse-free survival and overall survival for patients facing resectable and borderline resectable PDAC in the neo-adjuvant setting. If Phase 1 results are supportive, expanding to a broader population in this setting could enable more PDAC patients to benefit from ELI-002 7P, and also enhance the commercial opportunity for Elicio.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines